Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Female Sexual Dysfunction Pipeline Drugs Market Report Overview

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure, and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

The female sexual dysfunction pipeline drugs market research report provides comprehensive information on the therapeutics under development for female sexual dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for female sexual dysfunction and features dormant and discontinued projects.

Female Sexual Dysfunction Pipeline Drugs Market Segmentation by Targets

The key targets in the female sexual dysfunction pipeline drugs market are Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, D2 Dopamine Receptor, Melanocortin Receptor 4, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 2C among others. The Androgen Receptor is the leading target in the pipeline.

Female Sexual Dysfunction Pipeline Drugs Market Analysis by Targets

Female Sexual Dysfunction Pipeline Products Market Analysis by TargetsFor more target insights into the female sexual dysfunction pipeline drugs market, download a free report sample

Female Sexual Dysfunction Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the female sexual dysfunction pipeline products market are Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Melanocortin Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, and Adenosine Receptor A3 Agonist among others. Androgen Receptor Agonist is the leading MoA in the pipeline market.

Female Sexual Dysfunction Pipeline Products Market Analysis by Mechanisms of Action

Female Sexual Dysfunction Pipeline Products Market Analysis by Mechanisms of ActionFor more mechanisms of action insights into the female sexual dysfunction pipeline products market, download a free report sample

Female Sexual Dysfunction Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the female sexual dysfunction pipeline products market are oral, subcutaneous, nasal, topical, vaginal, and sublingual among others. Oral is the leading RoA.

Female Sexual Dysfunction Pipeline Products Market Analysis by Routes of Administration

Female Sexual Dysfunction Pipeline Products Market Analysis by Routes of AdministrationFor more routes of administration insights into the female sexual dysfunction pipeline products market, download a free report sample

Female Sexual Dysfunction Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the female sexual dysfunction pipeline drugs market are small molecule, synthetic peptides, cell therapy, and peptide. Small molecule is the leading molecule type.

Female Sexual Dysfunction Pipeline Drugs Market Analysis by Molecule Types

Female Sexual Dysfunction Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the female sexual dysfunction pipeline drugs market, download a free report sample

Female Sexual Dysfunction Pipeline Products Market - Competitive Landscape

Some of the leading companies in the female sexual dysfunction pipeline products market are S1 Biopharma Inc, Freya Pharma Solutions BV, Jupiter Wellness Inc, Kuhnil Pharmaceutical Co Ltd, Palatin Technologies Inc, Thomas Advanced Medical LLC, Autotelic Bio Inc, and Callitas Therapeutics Inc among others. S1 Biopharma Inc is the leading company in the female sexual dysfunction pipeline products market.

Female Sexual Dysfunction Pipeline Products Market Analysis by Companies

Female Sexual Dysfunction Pipeline Products Market Analysis by CompaniesTo know more about the leading players in the female sexual dysfunction pipeline products market, download a free report sample

Female Sexual Dysfunction Pipeline Products Market Report Overview

Key Targets Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, D2 Dopamine Receptor, Melanocortin Receptor 4, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 2C
Key Mechanisms of Action Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Melanocortin Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, and Adenosine Receptor A3 Agonist
Key Routes of Administration Oral, Subcutaneous, Nasal, Topical, Vaginal, and Sublingual
Key Molecule Type Small Molecule, Synthetic Peptide, Cell Therapy, and Peptide
Leading Companies S1 Biopharma Inc, Freya Pharma Solutions BV, Jupiter Wellness Inc, Kuhnil Pharmaceutical Co Ltd, Palatin Technologies Inc, Thomas Advanced Medical LLC, Autotelic Bio Inc, and Callitas Therapeutics Inc

Scope of Report

  • The pipeline guide provides a snapshot of the global therapeutic landscape of female sexual dysfunction.
  • The pipeline guide reviews pipeline therapeutics for female sexual dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in female sexual dysfunction therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates female sexual dysfunction therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for female sexual dysfunction

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for female sexual dysfunction.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the female sexual dysfunction pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

FAQs

  • The key targets in the female sexual dysfunction pipeline products market are Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, D2 Dopamine Receptor, Melanocortin Receptor 4, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 2C.

  • The key mechanisms of action in the female sexual dysfunction pipeline products market are Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Melanocortin Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, and Adenosine Receptor A3 Agonist.

  • The key routes of administration in the female sexual dysfunction pipeline products market are oral, subcutaneous, nasal, topical, vaginal, and sublingual.

  • The key molecule types in the female sexual dysfunction pipeline products market are small molecule, synthetic peptide, cell therapy, and peptide.

  • Some of the leading companies in the female sexual dysfunction pipeline products market are S1 Biopharma Inc, Freya Pharma Solutions BV, Jupiter Wellness Inc, Kuhnil Pharmaceutical Co Ltd, Palatin Technologies Inc, Thomas Advanced Medical LLC, Autotelic Bio Inc, and Callitas Therapeutics Inc.

What our clients have to say

More Reports

View More Reports